Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > バイオシミラー

Research Grade turenkibart (HS856246)

Research Grade turenkibart
Research Grade turenkibart
価格(USD): $
スペック:
  • 100ug
  • 1mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

概要
カタログ番号HS856246
説明
turenkibart (HS856246) is a research-grade recombinant antibody targeting IL17A.
Highlights
  • Research Grade — For PK/PD studies, assay development, and ADA research.
種反応性Human
アプリケーションELISA, Bioactivity: FACS, Functional assay, Research in vivo
宿主種Human
アイソタイプIgG1, Kappa
Human
クローン性 Monoclonal
ターゲット IL17A
純度 >95% as determined by SDS-PAGE.
アクセッション番号 Q16552
形態 Liquid
再構成 Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
発送 In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
別名 2761187-73-7
背景

Interleukin-17A (IL17A) is a ~17 kDa protein. Effector cytokine of innate and adaptive immune system involved in antimicrobial host defense and maintenance of tissue integrity. Signals via IL17RA-IL17RC heterodimeric receptor complex, triggering homotypic interaction of IL17RA and IL17RC chains with TRAF3IP2 adapter. This leads to downstream TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways ultimately resulting in transcriptional activation of cytokines, chemokines, antimicrobial peptides and matrix metalloproteinases, with potential strong immune inflammation. Plays an important role in connecting T cell-mediated adaptive immunity and acute inflammatory response to destroy extracellular bacteria and fungi. As a signature effector cytokine of T-helper 17 cells (Th17), primarily induces neutrophil activation and recruitment at infection and inflammatory sites. IL17A is the therapeutic target of secukinumab (Cosentyx).

1. Boisson, B. et al. (2013) Immunity 39, 676-86. PMID: 24120361
2. Kuestner, RE. et al. (2007) Journal of immunology (Baltimore, Md. : 1950) 179, 5462-73. PMID: 17911633
3. Wright, JF. et al. (2008) Journal of immunology (Baltimore, Md. : 1950) 181, 2799-805. PMID: 18684971
4. Liu, C. et al. (2009) Science signaling 2, ra63. PMID: 19825828
5. Puel, A. et al. (2011) Science (New York, N.Y.) 332, 65-8. PMID: 21350122
6. Fossiez, F. et al. (1996) The Journal of experimental medicine 183, 2593-603. PMID: 8676080
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • Research Grade turenkibart

    SDS-PAGE

    SDS-PAGE for Research Grade turenkibart

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: support@abinScience.com

ディストリビューターリスト